Current Report Filing (8-k)
28 June 2016 - 6:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
of report (Date
of earliest event reported): June 23, 2016
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07 Submission of Matters to a Vote of Security Holders
At the 2016 Annual Meeting of Stockholders
of Nektar Therapeutics, a Delaware corporation (the “Company”), held on June 23, 2016 (the “Annual Meeting”),
the following actions were taken. The proposals below are described in detail in the Company’s definitive proxy statement
dated May 13, 2016 for the Annual Meeting.
Proposal 1
Each of the individuals
listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors,
to serve on the Board of Directors of the Company until the 2019 Annual Meeting of Stockholders.
Nominee
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker
Non-Votes
|
|
R. Scott Greer
|
|
|
109,463,072
|
|
|
|
4,892,954
|
|
|
|
37,614
|
|
|
|
13,262,099
|
|
Christopher A. Kuebler
|
|
|
108,592,953
|
|
|
|
5,763,574
|
|
|
|
37,113
|
|
|
|
13,262,099
|
|
Lutz Lingnau
|
|
|
108,717,203
|
|
|
|
5,638,599
|
|
|
|
37,838
|
|
|
|
13,262,099
|
|
In addition to the directors elected above,
Robert B. Chess, Joseph J. Krivulka, Howard W. Robin, Roy A. Whitfield and Dennis Winger continue to serve as directors after the
Annual Meeting.
Proposal 2
The proposal to ratify the appointment,
by the audit committee of the Board of Directors, of Ernst & Young LLP as the independent registered public accounting firm
for the fiscal year ending December 31, 2016, as described in the proxy materials, was approved with approximately 99% of the shares
present or represented and voting at the Annual Meeting voting for the proposal and approximately 1% voting against the proposal.
For
|
|
|
Against
|
|
|
Abstain
|
|
|
126,889,341
|
|
|
|
733,721
|
|
|
|
32,677
|
|
Proposal 3
The proposal to approve the compensation
of the Company’s Named Executive Officers, on a non-binding advisory basis, was approved with approximately 97% of the shares
present or represented and voting at the Annual Meeting voting for the proposal and approximately 3% voting against the proposal.
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker Non-Votes
|
|
|
110,538,457
|
|
|
|
3,339,400
|
|
|
|
515,783
|
|
|
|
13,262,099
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEKTAR THERAPEUTICS
|
|
|
|
Date: June 27, 2016
|
By:
|
/s/
Gil M. Labrucherie
|
|
|
Gil M. Labrucherie
Senior Vice President and Chief Financial Officer
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2024 to May 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From May 2023 to May 2024